The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2020 | TOURMALINE-AL1: ixazomib and dexamethasone for AL amyloidosis
Giampaolo Merlini, MD, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, discusses the Phase III TOURMALINE-AL1 trial (NCT01659658), a study that compares the efficacy of ixazomib and dexamethasone versus physician’s choice in relapsed or refractory systemic light-chain (AL) amyloidosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
